国产99久久精品_欧美日本韩国一区二区_激情小说综合网_欧美一级二级视频_午夜av电影_日本久久精品视频

中信國健 CPGJ 
上海中信國健藥業股份有限公司(CPGJ)是由中國中信集團公司和上海蘭生國健藥業 有限公司共同投資的生物醫藥高新技術企業，專注于抗體藥物的研發、中試和產業化。公司自2002年創建以來，經過長期的不懈努力，現已成為國內抗體藥物企業的領軍者，提供覆蓋抗腫瘤、移植、自身免疫系統等重大疾病領域的靶向藥物,其應用效果得到了醫師和患者的廣泛贊譽。

作為一家以研發為基礎的生物制藥公司，中信國健已成功建立了國內領先的抗體藥物開發和產業化生產平臺，掌握了尖端的核心技術，并具備了持續開發新藥的創新能力。公司正在研制、臨床和銷售的抗體新藥達十多個，填補了國內抗體藥物領域的多個空白，研發實力和生產能力均處于國際領先水平。

現代化的生產設備，領先的生產工藝，嚴格的質量控制，確保了中信國健為患者提供優質的醫藥產品。作為亞洲規模最大的哺乳動物細胞培養生產基地之一，公司擁有國內最先進的3條750升、2條3000升的真核細胞培養生產線；同時，6條符合歐盟標準的5000升生產線正在建設中。公司還特別設計建立了涵蓋影響藥品質量所有因素，包括物料管理、生產管理、質量控制、質量保證、設備設施和包裝標簽的完善質量管理體系，其3000升生產線采用了具有國際領先水平的現場總線控制系統(FCS)以及過程控制系統(PCS)，該系統運用到的Delta VTM 數字自動化技術，對藥品的整個生產過程進行嚴密地不間斷地監測，最大程度地消除產品質量隱患和潛在的質量風險。

展望未來，中信國健將繼續發揮其在生物技術領域的研發優勢，為社會提供更多高效的靶向治療藥物。


Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a bio-pharmaceutical high-tech company which is co-invested by the CITIC Group and Shanghai Lansheng Guojian Pharmaceutical Co., Ltd. We focus on the R&D, pilot test and industrialization of antibody drugs. It has become a leader in the domestic antibody class of bio-pharmaceutical companies through long-term efforts, and providing targeted drugs covering major disease fields of Oncology, Transplantation, Systemic autoimmune diseases & etc.; its application effects have gained widespread recognition by physicians and patients.

As a bio-pharmaceutical company relying greatly on Research & Development, CPGJ has successfully built a leading domestic platform for the development of Antibody Drugs and their industrialization production, grasped sophisticated core technologies and now possesses the innovation ability to continuously develop new drugs. There are currently more than 10 new Antibody Drugs under development, clinical trials or sales, which have filled a crucial void in the domestic biomedical field, and its R&D strength and production capacity had reached international advanced levels.

The modern production equipments, leading production technology and strict quality control have ensured that CPGJ can provide high-quality medicines for patients. As one of the largest Asian production base for mammalian cells, CPGJ has obtained three 750-liters and two 3,000-liters most advanced eukaryotic cell culture production lines in China. Recently six 5000-liter lines are under construction by follow of the European Union's strict standards. The consummation quality control system included materials management, production management, QC, QA, equipment and packaging label is ensured the high volumes of quality products are produced. The 3,000-liter production lines adopted the internationally leading Field bus Control System (FCS) and the Process Control System, which used the latest DeltaVTM digital automation technology. It is continuously monitored during the whole processes in order to maximize the elimination of potential product quality risks.

Looking into the future, CPGJ will continue to make the most of the advantage in its R&D strength in the biotechnology field, and providing more effective targeted therapeutic drugs for society.